▁Ch 10.375
iros 10.84375
cience 12.265625
▁Group 7.41796875
▁pl 7.41015625
c 1.82421875
, 5.4609375
▁a 5.0625
▁leading 6.3125
▁bi 8.578125
oph 1.4951171875
arma 1.32421875
ce 0.394287109375
ut 3.4140625
ical 0.1109619140625
▁company 1.9404296875
, 1.5849609375
▁is 3.150390625
▁adv 7.7265625
ancing 0.060821533203125
▁its 2.375
▁cutting 7.1875
- 0.98828125
edge 0.1617431640625
▁research 4.0234375
▁by 5.171875
▁testing 7.20703125
▁two 7.6328125
▁prom 5.5625
ising 0.41943359375
▁anti 6.25390625
- 0.360107421875
can 4.49609375
cer 0.0347900390625
▁comp 5.64453125
ounds 0.1876220703125
▁for 3.458984375
▁human 5.390625
▁tri 3.21484375
als 0.0122222900390625
. 2.189453125
▁This 4.56640625
▁significant 7.81640625
▁mil 3.197265625
estone 0.0056915283203125
▁brings 5.125
▁hope 5.46484375
▁to 0.7861328125
▁millions 3.099609375
▁of 0.3759765625
▁cancer 2.451171875
▁patients 0.3095703125
▁world 2.419921875
wide 0.0202789306640625
, 1.986328125
▁as 2.205078125
▁the 2.1171875
▁potential 4.203125
▁new 4.08203125
▁treat 2.4140625
ments 0.002613067626953125
▁mark 6.5625
▁a 0.77978515625
▁cru 4.26953125
cial 0.0018024444580078125
▁step 1.1298828125
▁forward 1.2138671875
▁in 0.48291015625
▁the 0.9521484375
▁fight 1.171875
▁against 0.12152099609375
▁this 1.404296875
▁dev 2.244140625
ast 0.0014295578002929688
ating 0.005092620849609375
▁disease 0.1239013671875
. 0.1790771484375
<0x0A> 0.77734375
The 2.111328125
▁first 4.734375
▁comp 4.6328125
ound 0.299560546875
, 1.380859375
▁CS 8.3828125
- 0.91357421875
0 1.736328125
0 1.2548828125
1 0.93017578125
, 0.271240234375
▁has 2.296875
▁shown 2.037109375
▁remarkable 2.4765625
▁potential 2.830078125
▁in 0.6669921875
▁pre 2.99609375
cl 0.393310546875
in 2.1457672119140625e-05
ical 0.0009555816650390625
▁studies 0.85595703125
. 2.01953125
▁Develop 6.1171875
ed 0.0275726318359375
▁through 3.31640625
▁a 1.064453125
▁rig 4.2109375
orous 0.0171966552734375
▁research 3.2421875
▁process 1.08203125
, 0.7724609375
▁this 1.5849609375
▁small 5.66796875
▁mole 0.0657958984375
c 0.0021953582763671875
ule 9.107589721679688e-05
▁drug 3.09765625
▁has 1.888671875
▁demonstrated 2.07421875
▁impress 3.89453125
ive 0.004718780517578125
▁effic 2.5859375
acy 0.00014090538024902344
▁in 0.845703125
▁target 4.4921875
ing 0.04071044921875
▁and 2.09765625
▁killing 0.900390625
▁cancer 0.67919921875
▁cells 0.234375
▁while 2.72265625
▁minim 2.462890625
izing 0.070556640625
▁harm 1.91796875
ful 0.57958984375
▁effects 1.7685546875
▁on 0.407958984375
▁health 0.51611328125
y 0.0015897750854492188
▁cells 0.20654296875
. 0.312255859375
▁In 2.7890625
▁labor 4.61328125
atory 0.005931854248046875
▁experiments 2.990234375
, 0.1221923828125
▁CS 1.0146484375
- 0.0048065185546875
0 0.0015888214111328125
0 0.0008988380432128906
1 0.0017547607421875
▁exhib 4.96875
ited 0.1123046875
▁pot 2.3671875
ent 0.0443115234375
▁anti 0.85498046875
- 0.01354217529296875
can 0.546875
cer 0.0002567768096923828
▁activity 0.55224609375
▁against 1.6923828125
▁various 3.244140625
▁types 0.798828125
▁of 0.0126800537109375
▁tum 1.95703125
ors 0.6455078125
, 0.90625
▁making 6.7890625
▁it 0.11541748046875
▁a 0.62060546875
▁prom 0.90087890625
ising 9.560585021972656e-05
▁candidate 1.091796875
▁for 0.291748046875
▁further 2.85546875
▁development 2.185546875
. 0.81591796875
<0x0A> 0.429931640625
Dr 6.0859375
. 0.071533203125
▁Sarah 6.8671875
▁Collins 6.59765625
, 0.23974609375
▁Ch 7.24609375
iros 2.7578125
cience 0.062255859375
' 0.7421875
s 0.003414154052734375
▁Chief 0.81640625
▁Scient 0.56787109375
ific 0.00913238525390625
▁Officer 0.0216827392578125
, 0.276611328125
▁expressed 4.85546875
▁her 0.73974609375
▁enthus 2.4609375
ias 0.004726409912109375
m 4.5299530029296875e-05
▁about 1.646484375
▁the 0.438232421875
▁progress 2.58984375
▁made 1.564453125
▁with 3.212890625
▁CS 1.060546875
- 0.01351165771484375
0 0.00984954833984375
0 0.004055023193359375
1 0.00525665283203125
, 1.751953125
▁stating 2.2421875
, 0.517578125
▁" 0.031463623046875
O 3.109375
ur 0.0019016265869140625
▁research 2.41796875
▁team 1.146484375
▁has 0.55126953125
▁been 1.1923828125
▁working 0.7705078125
▁t 1.2548828125
ire 0.0015869140625
lessly 0.0004048347473144531
▁to 0.296875
▁develop 1.22265625
▁innov 4.71484375
ative 0.0026874542236328125
▁and 2.974609375
▁effective 0.85546875
▁treat 1.4736328125
ments 2.944469451904297e-05
▁for 0.39306640625
▁cancer 0.353759765625
. 1.099609375
▁The 2.599609375
▁prom 3.244140625
ising 0.00046825408935546875
▁pre 2.857421875
cl 0.062255859375
in 1.1444091796875e-05
ical 0.0003845691680908203
▁data 2.05859375
▁we 1.10546875
' 1.544921875
ve 0.2325439453125
▁seen 1.92578125
▁with 1.849609375
▁CS 0.1473388671875
- 0.0025806427001953125
0 0.00093841552734375
0 0.00038695335388183594
1 0.0006780624389648438
▁gives 3.84375
▁us 0.11541748046875
▁great 1.4208984375
▁hope 0.458984375
▁for 0.85791015625
▁its 3.173828125
▁potential 0.56591796875
▁to 0.7138671875
▁make 2.994140625
▁a 0.07940673828125
▁meaning 1.5029296875
ful 7.283687591552734e-05
▁impact 0.7568359375
▁on 0.4609375
▁patients 1.9931640625
' 0.99658203125
▁lives 0.08538818359375
." 0.671875
<0x0A> 0.1153564453125
The 1.8671875
▁second 0.42822265625
▁comp 0.3369140625
ound 0.0006246566772460938
, 0.128662109375
▁named 7.359375
▁CS 0.12939453125
- 0.0162200927734375
0 0.2498779296875
0 0.291259765625
2 0.2239990234375
, 0.01812744140625
▁is 1.26953125
▁a 1.96875
▁novel 2.2265625
▁imm 3.5546875
un 0.2379150390625
other 0.1939697265625
apy 0.1260986328125
▁agent 3.681640625
▁that 0.73681640625
▁har 4.97265625
ness 0.0010852813720703125
es 0.0010290145874023438
▁the 0.1175537109375
▁power 0.87353515625
▁of 0.0034503936767578125
▁the 0.330810546875
▁patient 1.6474609375
' 0.0104217529296875
s 0.00026535987854003906
▁own 0.77294921875
▁imm 0.09466552734375
une 0.003444671630859375
▁system 0.060516357421875
▁to 0.40234375
▁fight 1.2236328125
▁cancer 0.1409912109375
. 0.2088623046875
▁Im 6.3125
mun 0.2139892578125
other 0.005168914794921875
apy 0.1466064453125
▁has 1.53125
▁emer 3.052734375
ged 0.0001493692398071289
▁as 0.00797271728515625
▁a 0.442138671875
▁ground 4.48046875
bre 0.145751953125
aking 0.0002639293670654297
▁approach 1.80859375
▁in 1.9638671875
▁cancer 1.083984375
▁treatment 0.31201171875
, 0.59619140625
▁her 8.8671875
ald 0.0002086162567138672
ed 0.7998046875
▁for 1.0302734375
▁its 0.0633544921875
▁ability 0.67919921875
▁to 0.0011959075927734375
▁un 6.19921875
le 0.1845703125
ash 2.956390380859375e-05
▁the 0.2724609375
▁body 0.6533203125
' 0.0003235340118408203
s 0.0003237724304199219
▁imm 2.125
une 0.011993408203125
▁def 4.13671875
enses 0.01161956787109375
▁specifically 10.046875
▁against 0.454833984375
▁cancer 0.397216796875
▁cells 0.318359375
. 0.237060546875
▁CS 1.0126953125
- 0.0016851425170898438
0 0.0002796649932861328
0 7.855892181396484e-05
2 0.0020465850830078125
▁has 1.58203125
▁shown 1.02734375
▁remarkable 1.8154296875
▁potential 1.73828125
▁in 0.1636962890625
▁activ 8.6171875
ating 0.0008339881896972656
▁the 0.5283203125
▁imm 1.072265625
une 0.0027637481689453125
▁system 0.066162109375
' 2.671875
s 0.00021767616271972656
▁response 3.73828125
, 3.3359375
▁trigger 5.68359375
ing 0.00011813640594482422
▁a 1.0634765625
▁target 6.72265625
ed 0.01654052734375
▁attack 0.77978515625
▁on 0.73681640625
▁tum 2.1015625
ors 1.078125
. 1.126953125
<0x0A> 1.0703125
Ch 2.896484375
iros 0.262451171875
cience 0.011505126953125
' 0.55810546875
s 0.0017614364624023438
▁commit 7.9296875
ment 0.00017583370208740234
▁to 0.0225067138671875
▁rig 6.3203125
orous 0.07061767578125
▁scientific 2.35546875
▁research 0.27490234375
▁and 0.97705078125
▁development 1.60546875
▁has 1.009765625
▁p 5.3125
aved 0.0010290145874023438
▁the 0.006343841552734375
▁way 0.03668212890625
▁for 0.08880615234375
▁these 1.8603515625
▁adv 4.8828125
anc 0.266845703125
ements 1.8715858459472656e-05
. 0.81884765625
▁The 1.140625
▁company 0.54833984375
' 0.78759765625
s 0.0001882314682006836
▁dedicated 4.11328125
▁team 1.0185546875
▁of 0.52294921875
▁scient 1.001953125
ists 0.0005254745483398438
▁has 2.10546875
▁expert 6.95703125
ly 1.01953125
▁craft 2.734375
ed 0.0001671314239501953
▁these 1.662109375
▁comp 1.9150390625
ounds 0.00424957275390625
▁to 1.6689453125
▁specifically 5.7109375
▁target 0.291259765625
▁cancer 0.9521484375
▁cells 0.1802978515625
▁while 1.1337890625
▁minim 0.408203125
izing 0.0189666748046875
▁side 2.982421875
▁effects 0.0171661376953125
, 4.00390625
▁a 4.1328125
▁cru 2.509765625
cial 0.0008511543273925781
▁factor 1.7333984375
▁in 0.50634765625
▁developing 2.892578125
▁effective 1.4619140625
▁and 2.4453125
▁well 4.52734375
- 0.0098724365234375
tol 0.0185699462890625
er 4.673004150390625e-05
ated 0.001026153564453125
▁treat 0.6630859375
ments 1.4662742614746094e-05
. 0.5029296875
▁While 6.56640625
▁the 1.4384765625
▁comp 3.12109375
ounds 0.09759521484375
▁have 1.677734375
▁shown 1.5576171875
▁trem 3.306640625
end 2.2530555725097656e-05
ous 0.0012712478637695312
▁promise 0.1763916015625
▁in 0.48095703125
▁pre 1.2802734375
cl 0.020538330078125
in 7.271766662597656e-06
ical 0.0011119842529296875
▁studies 0.31005859375
, 0.07794189453125
▁the 1.7099609375
▁up 6.03515625
coming 0.0027313232421875
▁human 3.365234375
▁tri 0.2325439453125
als 4.5299530029296875e-06
▁will 0.424560546875
▁provide 1.44140625
▁critical 2.4921875
▁insight 1.53125
▁into 0.096435546875
▁their 0.73974609375
▁safety 2.724609375
▁and 0.250732421875
▁effic 0.1397705078125
acy 7.510185241699219e-06
▁in 0.98095703125
▁a 4.015625
▁clin 1.751953125
ical 0.0166473388671875
▁setting 0.056182861328125
. 0.056365966796875
<0x0A> 0.346435546875
H 5.89453125
uman 2.333984375
▁tri 0.1312255859375
als 1.049041748046875e-05
▁are 1.068359375
▁a 1.8251953125
▁vital 3.10546875
▁step 0.40087890625
▁in 0.607421875
▁the 0.5888671875
▁drug 2.880859375
▁development 0.365966796875
▁process 0.031494140625
, 0.630859375
▁ens 5.28125
uring 3.552436828613281e-05
▁that 0.6904296875
▁potential 3.13671875
▁treat 0.3125
ments 1.7762184143066406e-05
▁meet 1.7333984375
▁the 0.96630859375
▁necessary 3.60546875
▁effic 7.23828125
acy 0.00015985965728759766
▁and 0.326904296875
▁safety 0.0367431640625
▁criteria 2.439453125
. 0.91748046875
▁Ch 2.255859375
iros 0.006023406982421875
cience 0.002216339111328125
▁plans 4.76171875
▁to 0.028961181640625
▁en 2.748046875
roll 0.01242828369140625
▁a 1.34765625
▁diverse 1.7099609375
▁group 1.3056640625
▁of 0.000560760498046875
▁participants 2.216796875
, 1.51953125
▁representative 6.74609375
▁of 0.00518798828125
▁the 0.4072265625
▁populations 3.298828125
▁affected 2.361328125
▁by 0.00728607177734375
▁various 3.322265625
▁types 0.39013671875
▁of 0.0029811859130859375
▁cancer 0.1080322265625
. 0.919921875
▁By 2.96875
▁including 3.333984375
▁diverse 3.501953125
▁patient 1.291015625
▁populations 0.440673828125
, 0.58203125
▁the 0.669921875
▁tri 2.822265625
als 2.4080276489257812e-05
▁aim 3.708984375
▁to 0.0027599334716796875
▁capture 4.796875
▁a 1.7001953125
▁compreh 2.55078125
ensive 4.494190216064453e-05
▁understanding 0.91943359375
▁of 0.002689361572265625
▁how 2.109375
▁the 1.42578125
▁comp 1.0810546875
ounds 0.02752685546875
▁perform 3.03515625
▁across 3.130859375
▁different 1.4326171875
▁cancer 1.6689453125
▁types 0.1051025390625
▁and 1.25390625
▁patient 1.111328125
▁profiles 2.990234375
. 0.18359375
<0x0A> 0.79931640625
The 1.650390625
▁tri 1.8720703125
als 1.5854835510253906e-05
▁will 0.51025390625
▁be 1.8701171875
▁conducted 0.471923828125
▁in 0.8642578125
▁collaboration 1.7177734375
▁with 0.0005030632019042969
▁ren 4.625
owned 0.0006055831909179688
▁medical 1.9111328125
▁cent 1.3173828125
ers 0.0008516311645507812
, 1.2978515625
▁where 5.609375
▁both 6.06640625
▁comp 1.3427734375
ounds 0.0112762451171875
▁will 0.2117919921875
▁be 0.1712646484375
▁admin 0.8740234375
ister 5.447864532470703e-05
ed 4.684925079345703e-05
▁to 0.97705078125
▁carefully 5.71875
▁selected 0.485107421875
▁participants 0.7470703125
. 0.45458984375
▁Ext 9.171875
ensive 0.024017333984375
▁monitoring 1.9609375
▁and 0.96484375
▁analysis 2.78125
▁will 0.6025390625
▁be 0.3056640625
▁performed 2.01171875
▁to 1.0615234375
▁evaluate 2.541015625
▁the 0.39404296875
▁comp 1.87890625
ounds 0.037078857421875
' 0.1109619140625
▁effect 2.6953125
iveness 0.0258941650390625
, 1.361328125
▁side 3.42578125
▁effects 0.02197265625
, 0.055084228515625
▁and 0.10760498046875
▁overall 1.0546875
▁th 5.64453125
era 3.063678741455078e-05
pe 8.225440979003906e-06
ut 6.198883056640625e-06
ic 0.00151824951171875
▁potential 1.734375
. 0.17724609375
▁This 2.4296875
▁critical 2.689453125
▁phase 3.16015625
▁will 1.3046875
▁provide 1.087890625
▁in 2.431640625
valu 0.01263427734375
able 5.364418029785156e-06
▁ins 1.267578125
ights 1.8715858459472656e-05
▁into 0.2227783203125
▁the 0.327392578125
▁comp 1.0068359375
ounds 0.031158447265625
' 0.04608154296875
▁performance 3.673828125
, 1.5673828125
▁gu 6.3515625
iding 0.00292205810546875
▁research 3.337890625
ers 0.301025390625
▁toward 1.5576171875
▁potential 2.92578125
▁ref 9.1328125
in 0.0033473968505859375
ement 2.841796875
▁or 3.10546875
▁further 2.55859375
▁development 0.28857421875
. 0.485595703125
<0x0A> 0.1717529296875
Ch 1.28515625
iros 0.007213592529296875
cience 0.00231170654296875
' 0.99560546875
s 0.0013837814331054688
▁commit 1.7861328125
ment 0.0004210472106933594
▁to 0.00858306884765625
▁adv 2.95703125
ancing 0.05255126953125
▁innov 2.431640625
ative 0.0106964111328125
▁cancer 1.294921875
▁treat 0.2071533203125
ments 4.00543212890625e-05
▁extends 6.33203125
▁beyond 0.33447265625
▁these 3.033203125
▁two 3.474609375
▁comp 0.84619140625
ounds 0.0018138885498046875
. 0.1483154296875
▁The 0.2783203125
▁company 0.049713134765625
▁maintain 5.69921875
s 0.0001308917999267578
▁a 0.28564453125
▁robust 1.4033203125
▁pipeline 0.305908203125
▁of 0.08856201171875
▁research 3.099609375
▁and 1.0146484375
▁development 0.0201416015625
▁programs 2.330078125
, 0.55615234375
▁expl 6.0078125
oring 0.0004680156707763672
▁novel 2.93359375
▁th 1.796875
era 5.245208740234375e-06
pe 3.24249267578125e-05
ut 7.271766662597656e-06
ic 0.451416015625
▁targets 2.357421875
▁and 0.5400390625
▁treatment 4.38671875
▁strateg 2.25
ies 6.079673767089844e-06
. 1.2392578125
▁By 2.42578125
▁lever 2.369140625
aging 0.0002238750457763672
▁its 0.681640625
▁expert 2.107421875
ise 0.04443359375
▁in 0.72509765625
▁drug 1.923828125
▁discovery 1.091796875
▁and 0.380126953125
▁development 0.2489013671875
, 0.05047607421875
▁Ch 0.2216796875
iros 0.0017852783203125
cience 0.0008907318115234375
▁continues 3.591796875
▁to 0.0276947021484375
▁contribute 5.25
▁to 0.22412109375
▁the 0.30908203125
▁global 1.8408203125
▁effort 2.033203125
▁to 0.30078125
▁improve 2.7890625
▁patient 1.8291015625
▁out 0.451171875
comes 0.0011072158813476562
▁and 0.951171875
▁er 5.640625
ad 0.0030956268310546875
icate 1.8596649169921875e-05
▁cancer 0.1434326171875
. 0.252197265625
<0x0A> 0.154052734375
The 3.634765625
▁progress 5.59375
▁made 0.36572265625
▁by 2.40234375
▁Ch 0.2340087890625
iros 0.00304412841796875
cience 0.0014972686767578125
▁Group 7.15625
▁pl 3.296875
c 0.0025501251220703125
▁in 1.80859375
▁testing 7.30078125
▁these 2.015625
▁two 1.419921875
▁prom 0.8173828125
ising 0.00017011165618896484
▁anti 2.263671875
- 0.00522613525390625
can 0.0138092041015625
cer 0.00597381591796875
▁comp 0.346435546875
ounds 0.001819610595703125
▁for 2.357421875
▁human 0.31640625
▁tri 0.1912841796875
als 2.1457672119140625e-06
▁signals 5.15234375
▁a 0.72998046875
▁significant 1.40234375
▁step 2.498046875
▁forward 0.1441650390625
▁in 0.141357421875
▁the 0.2318115234375
▁fight 0.40478515625
▁against 0.00731658935546875
▁cancer 0.330322265625
. 0.09173583984375
▁These 2.8828125
▁potential 4.36328125
▁treat 0.5693359375
ments 1.1682510375976562e-05
▁hold 1.6552734375
▁trem 1.765625
end 3.7670135498046875e-05
ous 0.00034809112548828125
▁promise 0.2410888671875
▁to 3.7734375
▁revolution 4.1796875
ize 0.00466156005859375
▁cancer 1.1533203125
▁care 1.8642578125
, 0.96435546875
▁offering 2.046875
▁renew 7.73046875
ed 0.00010192394256591797
▁hope 0.007904052734375
▁to 0.435791015625
▁count 3.568359375
less 6.079673767089844e-06
▁individuals 3.89453125
▁and 2.67578125
▁their 0.364990234375
▁loved 0.599609375
▁ones 0.00017011165618896484
. 0.287109375
▁As 3.328125
▁the 0.677734375
▁tri 1.9306640625
als 1.8835067749023438e-05
▁progress 0.53662109375
, 0.1328125
▁research 4.16015625
ers 0.01129913330078125
▁and 1.869140625
▁patients 1.5400390625
▁al 0.5869140625
ike 8.940696716308594e-06
▁eager 6.5078125
ly 0.0005893707275390625
▁anticip 1.84765625
ate 0.0007390975952148438
▁the 0.23193359375
▁results 1.90625
▁that 4.171875
▁may 2.69140625
▁p 5.41796875
ave 0.0011835098266601562
▁the 0.0051116943359375
▁way 0.0152587890625
▁for 0.42529296875
▁a 1.365234375
▁new 0.6962890625
▁era 0.461669921875
▁in 1.431640625
▁cancer 0.1148681640625
▁treatment 0.378173828125
. 0.03570556640625
